Cameco (CCJ) Posts Q3 adj.-EPS of $0.26, Misses Street Estimates
More News related to CCJ
- Emerging Stock Report Initiates Independent Research Coverage on Coalcorp Mining Inc.
- Notable Analyst Rating Changes 11/23: SBUX, DE, SEED, NDAQ Upgraded; AGU, TRA, CIEN, FL Downgraded
- Raymond James Initiates Coverage on Cameco (CCJ) with a Market Perform
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Cameco's (CCJ) CEO, Grandey, Says Co. Considering Acquisitions, Calls Paladin an 'Interesting' Asset
More News related to Earnings
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- Human Genome Sciences (HGSI) To Offer Up to 12.5M Shares
- ZymoGenetics (ZGEN) Higher Ahead of Presentation
- Somaxon Pharmaceuticals (SOMX) Surges Ahead of FDA Action Date
- BioMarin Pharmaceutical (BMRN) Announces FDA Grants Orphan Drug Designation for 3,4-DAP
Cameco (NYSE: CCJ) reports Q3 adjusted EPS of $0.26, versus the analyst estimate of $0.33. Revenue for the quarter was $694 million, which compares to the estimate of $523.37 million.
Related Categories
EarningsStocks Mentioned
+0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
